Curaleaf's QMID Becomes First TGA-Registered Cannabis Inhaler in Australia
Image
London – October 01, 2026 -- Curaleaf International's Que Medical Inhalation Device (QMID) has become the first cannabis inhalation device to secure registration from Australia's Therapeutic Goods Administration, clearing the way for clinicians to prescribe a standardized-dosing device in a market that has treated more than one million patients since 2016.
TGA Grants Class IIb Status to QMID on September 15, 2026
The device, developed with Jupiter Research LLC, was listed in the Australian Register of Therapeutic Goods as a Class IIb Medical Device, marking the first regulatory approval in Australia for a device delivering Cannabis Sativa L. extracts via patient inhalation. The approval follows a multi-year regulatory process and arrives one year after QMID received EU Medical Device Registration.